BLU-808

About Blueprint Medicines

Blueprint Medicines is a precision therapy company acquired by Sanofi in 2025, operating as a focused subsidiary with enhanced global resources. The company has successfully commercialized AYVAKIT® (avapritinib) for systemic mastocytosis and GIST, validating its kinase-focused discovery platform. Its strategy centers on scaling this platform to expand into larger allergic/inflammatory disease populations and solid tumors, while incorporating new modalities like targeted protein degradation and AI/ML tools to drive future pipeline growth.

About Blueprint Medicines

Blueprint Medicines is a precision therapy company acquired by Sanofi in 2025, operating as a focused subsidiary with enhanced global resources. The company has successfully commercialized AYVAKIT® (avapritinib) for systemic mastocytosis and GIST, validating its kinase-focused discovery platform. Its strategy centers on scaling this platform to expand into larger allergic/inflammatory disease populations and solid tumors, while incorporating new modalities like targeted protein degradation and AI/ML tools to drive future pipeline growth.

Therapeutic Areas